CALADRIUS BIOSCIENCES INC (CLBS)
US1280582032 - Common Stock
CALADRIUS BIOSCIENCES INC
NASDAQ:CLBS (9/14/2022, 7:18:27 PM)
After market: 0.421 -0.01 (-1.27%)0.4264
-0.08 (-16.44%)
Company Profile
Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. The company is headquartered in Basking Ridge, New Jersey and currently employs 27 full-time employees. The firm is developing therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. The Company’s product candidates include CLBS16, CLBS12 and CLBS201. The CLBS16 (XOWNA) is an experimental regenerative medicine that is being studied in a Phase IIb study (the FREEDOM trial) in the United States for the treatment of coronary microvascular dysfunction. The CLBS12 (HONEDRA) is an experimental regenerative medicine being studied in Japan for the prevention of serious adverse consequences of critical limb ischemia. The CLBS201 is an experimental regenerative medicine designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic kidney disease.
Company Info
CALADRIUS BIOSCIENCES INC
110 Allen Road, Second Floor
Basking Ridge NEW JERSEY 07920
P: 19082292590.0
CEO: David J. Mazzo
Employees: 27
Website: https://www.caladrius.com/
CLBS News
Company to commence trading on The Nasdaq Capital Market under Ticker Symbol “LSTA” Lisata has approximately $76 million in cash and investments following...
All Merger-related proposals approved at the Annual Meeting of Stockholders...
2 years ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayWe're starting off the final trading day of the week with an overview of the biggest pre-market stock movers for Friday!
Study to be part of Roche’s Morpheus Platform designed to enable more rapid and efficient development of novel cancer immunotherapy combinations ...
Merger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisata...
2 years ago - Halper Sadeh LLPSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates PING, CLBS, MANT/PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
CLBS Twits
Here you can normally see the latest stock twits on CLBS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
